Phagocytic checkpoint blockade, including anti-CD47 therapy and PD-L1 blockade, stimulates the innate and adaptive immune systems to generate anti-tumor responses, combining them with existing cancer immunotherapy strategies to improve the response rate to tumor treatment [26]. This evidence concerns the gene CD274 and neoplasm.